Hologic's EBIT per Share for the
three
months ended in Dec. 2025 was €0.97.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €2.96.
During the past 12 months, the average EBIT per Share Growth Rate of Hologic was -11.80% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -18.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -12.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Hologic's EBIT per Share or its related term are showing as below:
FRA:HO1'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -40.5 Med: 17.8 Max: 203.1
Current: -18.7
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Hologic was 203.10% per year. The lowest was -40.50% per year. And the median was 17.80% per year.
FRA:HO1's 3-Year EBIT Growth Rate is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 9.5
vs FRA:HO1: -18.70
Hologic's EBIT for the
three
months ended in Dec. 2025 was €220 Mil.
Hologic (FRA:HO1) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Hologic EBIT per Share Related Terms
Hologic EBIT per Share Historical Data
* Premium members only.
The historical data trend for Hologic's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.96
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hologic (FRA:HO1) has a EBIT per Share of €2.96 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Hologic and its competitors.
Is Hologic's EBIT per Share too high?
Hologic's current EBIT per Share is €2.96. Overall, Hologic has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Hologic's EBIT per Share compare to WST and COO?
Hologic's EBIT per Share of €2.96 can be compared against companies in the Medical Devices & Instruments industry. The industry median EBIT per Share is 9.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.50, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Hologic and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hologic's current EBIT per Share is €2.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hologic stock overvalued right now?
Hologic (FRA:HO1) has a current EBIT per Share of €2.96. The stock's GF Value™ is €70.17, compared to a current price of €65.00 — trading 7.4% below its estimated fair value. The current EBIT per Share is €2.96. Hologic's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Hologic (FRA:HO1), the current EBIT per Share is €2.96 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hologic (FRA:HO1) Overvalued in 2026?
Based on GuruFocus' analysis, Hologic stock appears to be undervalued.
The current stock price of €65.00 is trading 7.4% below its estimated GF Value™ of €70.17.
Key valuation signals for FRA:HO1:
EBIT per Share: €2.96
GF Value™: €70.17 vs. price of €65.00 (7.4% below fair value)
No single metric tells the full story. See the FRA:HO1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
57GF Score
Get the complete analysis for FRA:HO1
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HO1 has been successfully added to your 
